Mylan (MYL) Surges on DOJ EpiPen Medicaid Rebate Settlement
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mylan (NASDAQ: MYL) is trading up 9% after-hours Friday after the company it agreed to the terms of a $465 million settlement with the DOJ and other government agencies that will resolve questions that have been raised about the classification of EpiPen for purposes of the Medicaid Drug Rebate Program.
The company's 2016 guidance was also cut, but very little.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan (MYL) Announces Restructuring Program; Sees Workforce Impact
- Anthera Pharma (ANTH) Shares Climb 50%
- Nu Skin Enterprises (NUS) weekly call implied volatility elevated into guiding FY17 EPS below views
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!